- Home
- CSTL vs EVMN Comparison
CSTL vs EVMN Comparison
Compare CSTL & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSTL | EVMN |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 806.3M | 892.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CSTL | EVMN |
|---|---|---|
| Price | $24.90 | $23.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $47.17 | $43.29 |
| AVG Volume (30 Days) | ★ 398.2K | 286.3K |
| Earning Date | 05-04-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $344,229,000.00 | N/A |
| Revenue This Year | $2.42 | N/A |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.66 | N/A |
| 52 Week Low | $14.59 | $13.89 |
| 52 Week High | $44.28 | $33.20 |
Technical Indicators
Market Signals| Indicator | CSTL | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 26.58 | 46.53 |
| Support Level | $24.89 | $21.40 |
| Resistance Level | $34.97 | $33.20 |
| Average True Range (ATR) | 1.02 | 2.08 |
| MACD | 0.13 | -0.36 |
| Stochastic Oscillator | 4.41 | 33.61 |
Price Performance
Historical ComparisonAbout CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.